GlassScriptPhysician profile
Divyang M Parikh
NPI 1215994926
$360.09
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.25 · 2020: $92.58 · 2021: $145 · 2022: $28.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $94.25 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.01 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $51.48 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.02 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $25.00 | 2021 | |
| Alfasigma USA, INC. | $16.23 | 2020 | |
| Braintree Laboratories, INC. | $14.50 | 2021 | |
| Merck Sharp & Dohme LLC | $14.43 | 2020 | |
| Qol Medical, LLC | $13.96 | 2021 | |
| Abbvie INC. | $13.52 | 2021 | |
| Redhill Biopharma INC. | $12.69 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divyang Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.